Research And Development

Research and Development

Our Mission

Develop the most competitive and focused pipeline 
to address unmet patient needs  
in a highly differentiated way
to drive the growth of Teva

 

 Areas of Focus

 
 

Establish
leadership in

Build a unique
platform
for

Sustain and
leverage
strength
in

Achieve leading
presence
in

Selectively
Invest

High-barrier Gx (generics)
NTEs (New
Therapeutic Entities)
CNS (Central Nervous System)
Respiratory
Oncology
Women's Health
Biologics
 

 Our Strategy

 

NTE - New Therapeutic Entity

Known molecules that are formulated,
delivered, or used in a novel way to

address unmet patient needs

 

 UK Clinical Drug Development Collaboration

 
 
 
Michael Hayden 

Dr. Michael Hayden announces new collaboration with the UK’s National Health Service (NHS) on clinical development and Dementia research, saying, “The relationship between Teva, Israel and the UK is a long and fruitful one and I am proud that we can now add another example of us working together as partners for innovation and health.”

Read more about UK Clinical Drug Development Collaboration >>

 

 The National Network of Excellence in Neuroscience (NNE)

 
 
 
Michael Hayden 

In the past year, Teva established the National Network of Excellence in Neuroscience (NNE) led by Dr. Michael Hayden, President of Global R&D and Chief Scientific Officer. The aim of the NNE is to promote neuroscience research in Israel. The NNE creates a common framework for the activities of Israeli neuroscience researchers at leading academic institutions and medical centers.

Read more about NNE >>

 

 Recently Recruited Leaders

 
 
Michael Hayden President of Global R&D and CSO
Michael Hayden

World leading expert on Huntington Disease

Killam Professor of Medical Genetics and Canada Research Chair in Human Genetics and Molecular Medicine, University of British Columbia

Founder and Director/Senior Scientist, Centre for Molecular Medicine and Therapeutics, University of British Columbia

Founder, biotechnology companies: NeuroVir; Aspreva Pharmaceuticals; Xenon Pharmaceuticals Inc.

Training in Internal Medicine, post-doctoral fellowship Harvard Medical School

Jon Isaacsohn Chief Medical Officer
Jon Isaacsohn

Former EVP, head of Medical & Regulatory Medpace

Training in Internal  Medicine and Cardiology Harvard Medical School

Member of the  cardiology faculty Yale Medical School

Co-founder Metabolic & Atherosclerosis Research Center, Cincinnati

Volker Knappertz VP of MS Clinical
Volker Knappertz

US Board certified neurologist Neurology residence at Yale Medical School

15 years of pharma experience Bayer, Medimmune/AZ

Most recent position: Head of Clinical Development, Neurology Medimmune/AZ